🇺🇸 FDA

Company profile · Sponsor

Theravance

Theravance Biopharma Ireland Umited

TBPH · NYSE biotech GEORGE TOWN, GRAND CAYMAN, CA, IE
Pipeline
24
Drugs
1
Patents
8

Quick answer

Theravance (TBPH) is a biotech company. headquartered in GEORGE TOWN, GRAND CAYMAN, CA, IE. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 1 drug, and 8 patents to this profile..

Company facts

Ticker TBPH
Exchange NYSE
Company type biotech
Headquarters GEORGE TOWN, GRAND CAYMAN, CA, IE
SEC CIK 0001583107

Pipeline (24)

Search pipeline →

  1. Revefenacin

    Theravance

    Chronic Obstructive Pulmonary Disease, COPD

    phase 3 small molecule completed

    2 trials

  2. TD-1473 Dose A

    Theravance

    Ulcerative Colitis (UC)

    phase 3 small molecule terminated

    2 trials

  3. TD-4208

    Theravance

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 3 small molecule completed

    4 trials

  4. ampreloxetine

    Theravance

    Symptomatic Neurogenic Orthostatic Hypotension

    phase 3 small molecule active

    4 trials

  5. 400 microgrammes GSK961081

    Theravance

    Pulmonary Disease, Chronic Obstructive

    phase 2 small molecule completed

    1 trial

  6. Placebo

    Theravance

    Chronic Obstructive Pulmonary Disease, COPD

    phase 2 small molecule completed

    1 trial

  7. Placebo

    Theravance

    Crohn's Disease

    phase 2 small molecule terminated

    1 trial

  8. Revefenacin Inhalation Solution [Yupelri]

    Theravance

    COPD

    phase 2 small molecule completed

    1 trial

  9. TD-0903

    Theravance

    Acute Lung Injury (ALI) Associated With COVID-19

    phase 2 small molecule completed

    2 trials

  10. TD-1211

    Theravance

    Healthy

    phase 2 small molecule completed

    2 trials

  11. TD-1211

    Theravance

    Opioid Induced Constipation

    phase 2 small molecule completed

    2 trials

  12. TD-1211

    Theravance

    Opioid-induced Constipation (OIC)

    phase 2 small molecule completed

    1 trial

  13. TD-1792

    Theravance

    Staphylococcal Skin Infection

    phase 2 small molecule completed

    1 trial

  14. TD-4208

    Theravance

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule completed

    1 trial

  15. TD-4208

    Theravance

    COPD

    phase 2 small molecule completed

    2 trials

  16. TD-5108

    Theravance

    Chronic Constipation

    phase 2 small molecule completed

    1 trial

  17. TD-8236

    Theravance

    Asthma

    phase 2 small molecule completed

    2 trials

  18. TD-9855

    Theravance

    Attention-Deficit/Hyperactivity Disorder

    phase 2 small molecule completed

    1 trial

  19. TD-9855

    Theravance

    Neurogenic Orthostatic Hypotension

    phase 2 small molecule completed

    1 trial

  20. TD-9855 Group 1

    Theravance

    Fibromyalgia

    phase 2 small molecule completed

    1 trial

  21. Telavancin

    Theravance

    Infection

    phase 2 small molecule completed

    1 trial

  22. Velusetrag

    Theravance

    Gastroparesis

    phase 2 small molecule completed

    1 trial

  23. velusetrag dose 1

    Theravance

    Gastroparesis

    phase 2 small molecule completed

    1 trial

  24. Ampreloxetine

    Theravance

    Symptomatic Neurogenic Orthostatic Hypertension

    phase 1 small molecule completed

    1 trial

Drugs (1)

Search drugs →

  1. telavancin

    VIBATIV

    INJECTION approved

    J01XA03

Patents (8)

Search patents →

  1. US 12384761

    Imidazolo indazole compounds as JAK inhibitors

    Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12358931

    3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl) propanenitrile as a JAK kinase inhibitor

    Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12351561

    Crystalline (2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof

    Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12285417

    Methods for treating chronic obstructive pulmonary disease

    Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12258316

    Biphenyl compounds useful as muscarinic receptor antagonists

    Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12239638

    Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound

    Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12172994

    Pyrimidine compound as JAK kinase inhibitor

    Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12122773

    Crystalline hydrate of a JAK inhibitor compound

    Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Theravance?

Theravance (TBPH) is a biotech company. headquartered in GEORGE TOWN, GRAND CAYMAN, CA, IE. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 1 drug, and 8 patents to this profile..

What pipeline programs does Theravance sponsor?

We track 24 ClinicalTrials.gov-linked programs for Theravance, including Revefenacin and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Theravance company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.